In conclusion, for patients with early RA and almost exclusively high disease activity, qualitative data and NWMAs suggest that the combination of a TNF or non-TNF biologic with MTX improves disease activity and DAS-defined remission when compared with either biologic or MTX monotherapy. This evidence concerns the gene TNF and rheumatoid arthritis.